SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 0 of 16
Word Count: 1461
Character Count: 9556

Document Content:

As filed with the Securities and Exchange Commission
on May 15, 2026

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Synergy CHC Corp.

(Exact Name of Registrant as Specified in its
Charter)

Nevada 2833 99-0379440

(State or
other jurisdiction of
incorporation or organization) (Primary Standard Industrial
Classification Code Number) (I.R.S. Employer
Identification No.)

770 Roosevelt Trail STE 8 #1016

N. Windham, Maine 04062

(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive office)

Jack Ross

Chief Executive Officer

c/o Synergy CHC Corp.

770 Roosevelt Trail STE 8 #1016

N. Windham, Maine 04062

(Name, address, including zip code, and telephone
number, including area code, of agent for service)

Copies to:

W. David Mannheim
Michael K. Bradshaw, Jr.
Nelson Mullins Riley & Scarborough LLP
301 Hillsborough Street, Suite 1400
Raleigh, NC 27603

Approximate date of commencement
of proposed sale to public: From time to time after this registration statement becomes effective.

If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box. ☒

If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting
company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☐

If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities Exchange
Commission, acting pursuant to section 8(a), may determine.

The information contained
in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the Registration Statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities.
Neither we nor the selling stockholder are soliciting offers to buy these securities in any state where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED MAY 15, 2026

101,710,000 Shares of Common Stock

Synergy CHC Corp.

This prospectus relates to
the resale from time to time of up to 101,710,000 shares of common stock, par value $0.00001 (the “common stock”), of Synergy
CHC Corp., a Nevada corporation (the “Company,” “we,” “our,” and “us”), by Hudson Global
Ventures, LLC (the “Selling Stockholder”). The 101,710,000 shares of common stock registered under the registration statement
of which this prospectus forms a part (the “Registration Statement”) consists of (i) 100,000,000 shares of common stock (the
“ELOC Shares”) issued to the Selling Stockholder as a result of the Company directing the Selling Stockholder to purchase
such shares from time to time pursuant to an Equity Purchase Agreement dated May 8, 2026 (the “ELOC Purchase Agreement”),
(ii) 1,540,000 shares of common stock (the “Warrant Shares”) issuable upon the exercise of a warrant (the “Warrant”)
issued to the Selling Stockholder as a commitment fee upon the execution of the ELOC Purchase Agreement, and (iii) shares of common stock
previously issued to the Selling Stockholder in connection with the consulting agreements between Selling Stockholder and the Company (the
“Existing Shares”). See the section of this prospectus entitled “The ELOC Purchase Agreement” for a description
of the terms and conditions of the ELOC Purchase Agreement, including the Warrant Shares and the Warrant.

The Selling Stockholder may
sell the shares of common stock described in this prospectus in a number of different ways and at varying prices determined by the prevailing
market price for the shares or in negotiated transactions. We are not selling any securities under this prospectus and will not receive
any of the proceeds from the sale of shares of common stock by the Selling Stockholder. However, we may receive up to $36,000,000 in
aggregate gross proceeds under the ELOC Purchase Agreement. We provide more information about how the Selling Stockholder may sell its
shares of common stock in the section of this prospectus entitled “Plan of Distribution.”

The Selling Stockholder
is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities
Act”) with respect to the resale of its shares of common stock hereunder.

We will pay the expenses incurred
in registering the common stock described in this prospectus, including legal and accounting fees. To the extent the Selling Stockholder
decides to sell its shares of common stock, we will not control or determine the price at which the shares are sold.

Our common stock is listed
on the Nasdaq Capital Market under the symbol “SNYR”. The last reported sale price of our common stock on Nasdaq on May 13,
2026, was $0.30 per share.

We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments
or supplements carefully before you make your investment decision.

We are a “smaller reporting
company” as defined in the federal securities laws and will be subject to reduced public company reporting requirements. See “Prospectus
Summary — Implications of Being a Smaller Reporting Company”.

Investing in our common
stock involves a high degree of risk. See “Risk Factors” beginning on page 9 of this prospectus and under similar headings
in the documents incorporated by reference into this prospectus for a discussion of information that should be considered in connection
with an investment in our securities.

Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is           ,

TABLE OF CONTENTS

Page

ABOUT THIS PROSPECTUS	ii

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	iii

PROSPECTUS SUMMARY	1

RISK FACTORS	9

USE OF PROCEEDS	10

SELLING STOCKHOLDER	11

THE ELOC PURCHASE AGREEMENT	12

PLAN OF DISTRIBUTION	16

DESCRIPTION OF CAPITAL STOCK	17

LEGAL MATTERS	21

EXPERTS	21

WHERE YOU CAN FIND MORE INFORMATION	21

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE	22

ABOUT THIS PROSPECTUS

This prospectus is part of
a registration statement on Form S-1 that we have filed with the Securities and Exchange Commission (the “SEC”) pursuant to
which the Selling Stockholder may, from time to time, offer and sell or otherwise dispose of the shares of our common stock described
in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the shares of our common stock offered

We may also file a prospectus
supplement or post-effective amendment to the Registration Statement that may contain material information relating to this offering.
The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus. If there
is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment,
you should rely on the prospectus supplement or post-effective amendment, as applicable. The Registration Statement includes exhibits
that provide more detail regarding the matters discussed in this prospectus. You should read this prospectus, any post-effective amendment,
and any applicable prospectus supplement and the related exhibits filed with the SEC before making your investment decision. The Registration
Statement and the exhibits can be obtained from the SEC, as indicated under the section entitled “Where You Can Find More Information.”